Table 2 Characteristics and clinical outcome of patients with BCR::ABL1-like ALL

31/F

SR

9,44

B-common

47,XX + mar[4]/46,XX[12]

CRLF2-r

Fusion partner not identified

(70% of cells)

Non-mutated

CR MRD negative

Relapse after maintenance therapy

Dead

21/M

SR

21,22

B-common (expression of CRLF2: 79%)

ND

CRLF2-r

CRLF2::IGH

(80% of cells)

Non-mutated

CR MRD negative

Sudden death in CR1 during consolidation—pulmonary embolism

Dead

55/M

HR

200

B-common (expression of CRLF2: 100%)

ND

CRLF2-r

CRLF2::IGH

(50% of cells)

Non-mutated

CR MRD negative

Death after induction—MODS, PRES

Dead

32/M (19 at initial diagnosis)

HR

14,5

B-common (expression of CRLF2: 99%)

45,XY,del(9)(p21),der(19)(:19p13.2 → 19q13.4::?),-20[9]/45,idem,der(17)(?::17p11.2 → 17qter)[2]/45,idem,der(3)(3pter → 3q13.3::?),-14, + der(19)(:19p13.2 → 19q13.4::?)[1]/45,idem,der(3)(3pter → 3q13.3::?)[1],44,idem,-14,der(17)( ?::17p11.2 → 17qter)[1]/44,idem,-14[1]/46,XY,der(3)(3pter → 3q13.3::?),del(9)(p21),add(14)(qter)[1]/46,XY,der(3)(3pter → 3q13.3::?)[1].nuc ish(CRLFx2)(5’CRLF sep 3’CRLFx1)[40/50],(IGHx2)(3’IGH sep 5’IGHx1)[98/100],(PBX1 × 2,HLFx2,E2Ax1)[43/50]

CRLF2-r

CRLF2::IGH

(75% of cells)

JAK2 c.2049A>C (p.R683S)

CR MRD negative

alloHSCT in CR1; relapse after 13 years; CRLF2-r diagnosed during relapse; CR2 MRD negative after reinduction

Alive

32/M

HR

127

Pro-B

ND

ABL1-r

Fusion partner not identified

(15% of cells)

NA

CR MRD positive

alloHSCT in CR1; relapse after 3 months post-alloHSCT

Dead

29/M

HR

55,1

B-common

41–45,XY,-6[2],-18[3],-20[3],-21[2],-22[3][cp10]/46,XY[11]

ABL2-r

Fusion partner not identified

(30% of cells)

NA

CR MRD positive

alloHSCT in CR1

Alive